News for Halozyme Therapeutics, Inc. (HALO)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

On March 3, 2025, Jeffrey Henderson, Director at Halozyme Therapeutics Inc (HALO), sold 5,000 shares of the company, according to a SEC Filing. Following this t

On February 27, 2025, Michael Labarre, Senior Vice President and Chief Technical Officer at Halozyme Therapeutics Inc (HALO), executed a sale of 21,697 shares o

Halozyme Therapeutics Inc (HALO), a leading biopharmaceutical company known for its innovative drug delivery solutions, announced on February 26, 2025, that its

PR NewswireSAN DIEGO, Feb. 26, 2025 SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that D

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Total Revenue: Exceeded $1 billion for the first time in 2024, growing 22% over the prior year.Royalty Revenue: Increased 27% to $571 million in 2024.Net Incom

Feb 18, 2025 / 09:30PM GMTOperator Good afternoon. My name is Karen, and I will be your conference moderator today. At this time, I would like to welcome everyo

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ETCompany ParticipantsTram Bui - Vice President,...

The following slide deck was published by Halozyme Therapeutics, Inc.

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireSAN DIEGO, Feb. 18, 2025 Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 millionFou

Quarterly Revenue: $298 million, surpassing the estimated $288.24 million, marking a 30% increase year-over-year.Quarterly EPS: $1.06, slightly above the estim

Morgan Stanley has assumed coverage of Halozyme (HALO) with an overweight rating, citing its diversified revenue stream. Read more here.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.